|
Education and Outreach to Tribal Producers through the Tribal Food Safety Alliance
|
Food and Drug Administration |
August 20, 2026
25d left
|
$500k |
|
|
Use of Digital Health Technologies in Clinical Investigations to Support Drug and Biological Product Development (U01) Clinical Trials Optional
|
Food and Drug Administration |
August 20, 2026
25d left
|
$1.1M |
Nonprofits
|
|
Cooperative Agreement to Support Shellfish Safety Assistance Project
|
Food and Drug Administration |
August 21, 2026
26d left
|
$500k |
|
|
Research, Education, and Outreach on Botanical Natural Products
|
Food and Drug Administration |
August 21, 2026
26d left
|
$5.1M |
|
|
Federal and University Partnership to Improve the Safety of Seafood from the Gulf of America
|
Food and Drug Administration |
August 21, 2026
26d left
|
$125k |
|
|
Minor Use Minor Species Development of Drugs (R01)
|
Food and Drug Administration |
January 29, 2027
|
$250k |
Nonprofits
|
|
NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens
|
Food and Drug Administration |
April 1, 2027
|
$200k |
|
|
Animal Food Regulatory Program Standards Implementation Development and Maintenance, with Mutual Reliance Initiatives Clinical Trials Not Allowed
|
Food and Drug Administration |
April 1, 2027
|
$300k |
|
|
Laboratory Flexible Funding Model (LFFM)
|
Food and Drug Administration |
January 11, 2028
|
$1.5M |
|
|
Reissue of RFA-FD-22-001 - Efficient and Innovative Natural History Studies Addressing Unmet Needs in Rare Diseases (R01 Clinical Trials Optional)
|
Food and Drug Administration |
February 8, 2028
|
$600k |
|
|
Animal and Veterinary Innovation Centers (U18)
|
Food and Drug Administration |
May 12, 2028
|
$1.2M |
|
|
Reissue of RFA-FD-23-001- Clinical Studies of Orphan Products Addressing Unmet Needs of Rare Diseases (R01 Clinical Trials Required)
|
Food and Drug Administration |
May 16, 2028
|
$900k |
|
|
Vet-LIRN Capacity-Building Project and Equipment Grants (U18)
|
Food and Drug Administration |
September 4, 2028
|
$2.5M |
Nonprofits
|
|
AAV Vector manufacturing for diseases affecting very small populations
|
Food and Drug Administration |
Rolling / TBD
|
$600k |
Nonprofits
|
|
Enhancing Innovations in Advanced Manufacturing Technologies for Vaccines against Influenza and Emerging Infectious Diseases
|
Food and Drug Administration |
Rolling / TBD
|
$500k |
Nonprofits
|
|
Accessibility Assessments
|
National Park Service |
Rolling / TBD
|
$450k |
Nonprofits
|
|
FDA's National Curriculum Standard Development and Training Delivery and Development (ORA/OTED) (U18) Clinical Trial Not Allowed
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Integrated Pathogen Reduction Technologies for whole blood and blood components for transfusion (R01) Clinical Trial Not Allowed
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Development and Maintenance of the Animal Feed Regulatory Program Standards with Optional Coordinated Preventive Control Regulatory Activities and Capacity Building (U18) Clinical Trial Not Allowed
|
Food and Drug Administration |
Rolling / TBD
|
— |
|
|
An evidence-based clinical practice guideline for dental pain (surgical and non-surgical)
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Retail Food Safety Association Collaboration (U18) Clinical Trial Not Allowed
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
NARMS Cooperative Agreement Program to Strengthen Antibiotic Resistance Surveillance in Retail Food Specimens (U01) Clinical Trials Not Allowed
|
Food and Drug Administration |
Rolling / TBD
|
— |
|
|
Exploring the use of Real-World Data to Generate Real-World Evidence in Regulatory Decision-Making (U01) Clinical Trials Optional
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Incorporating cost effectiveness & societal outcomes into FDA opioids model (U01)
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Smoking Machine Adaptor Design Project for ENDS, Cigars, and Heated Tobacco Products
|
Food and Drug Administration |
Rolling / TBD
|
$2M |
|
|
Drug Development Science Support (U01)
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
CBER FY20 FOA for AAV vector manufacturing for diseases affecting very small populations (R01) Clinical Trial Not Allowed
|
Food and Drug Administration |
Rolling / TBD
|
$400k |
Nonprofits
|
|
Development of methods for evaluating the impact of small design differences in the user interface of drug-device combination products on generic substitutability
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
Individuals
|
|
PBPK Models to Aid the Development of Generic Dermatological Products
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
Individuals
|
|
PBPK Models of Oral Absorption to Simulate the Results of Bioequivalence Studies
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
Individuals
|
|
Implementation of the National Evaluation System for Health Technology (NEST) Coordinating Center (CC)
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
CFD Models to aid the development of generic inhalation products
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Analgesic, Anesthetic and Addiction Clinical Trials Innovations, Opportunities, and Networks (ACTTION)
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
SmartTots (Strategies for Mitigating Anesthesia-Related neuroToxicity in Tots) Public-Private Partnership
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Quantify the expression of metabolizing enzymes and transporter proteins in lung, eye and skin tissue in relevant animal models and humans
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Impulse Oscillometry Endpoint Sensitivity to Regional Lung Function Changes using Computational Fluid Dynamics (CFD)
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Dermal Physiologically-Based Pharmacokinetic (PBPK) Models Accounting for the Absorption and Evaporation of Vehicle/Co-Solvent Following the Application of Generic Dermatological Products
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Expanding the Opioids System Model to more comprehensively incorporate fentanyl, stimulants use, polysubstance use and associated outcomes.
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Development of a model selection method for population pharmacokinetics analysis by deep-learning based reinforcement learning
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Drug Development Tools Research Grants (U01 Clinical Trial Optional)
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|
|
Minor Use Minor Species Development of Drugs (R01) Clinical Trials Not Allowed
|
Food and Drug Administration |
Rolling / TBD
|
— |
Nonprofits
|